- Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis — Active Not Recruiting • Phase II • Gastroenterology • NCT06029972.
- A new drug called tilpisertib fosmecarbil tested against placebo in patients with moderate-to-severe ulcerative colitis to see if it improves symptoms by week 12.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with tilpisertib fosmecarbil with participants treated with placebo. The primary objective of this study is to demonstrate the efficacy of tilpisertib fosmecarbil, compared to placebo control, in achieving Clinical Response at Week 12. Conditions: Ulcerative Colitis Interventions: Tilpisertib Fosmecarbil, Placebo Lead Sponsor: Gilead Sciences Planned Enrollment: 176 participants